Related Experiment Videos
Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors
J West1, T Munoz-Antonia, J G Johnson
1Department of Otolaryngology and Head and Neck Surgery, Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9297, USA.
Objective:
Resistance to transforming growth factor (TGF)-beta-mediated cell growth inhibition is a well-known pathogenic mechanism in epithelial neoplasia. TGF-beta signaling requires normal function of downstream mediators such as TGF-beta receptors (TbetaRs) and Smad proteins. The goal of this study is to investigate the expression of components of the TGF-beta signaling pathway in follicular tumors of the thyroid.
Study Design:
Twenty follicular thyroid neoplasms were classified as adenomas (11) or minimally invasive follicular carcinomas (9) according to current pathological criteria. Protein expression was evaluated to identify differences between benign and malignant tumors that could be used as an adjunct to histopathological analysis.
Methods:
Paraffin-embedded tissue sections containing tumor and adjacent nonneoplastic parenchyma were analyzed by immunohistochemistry for the expression of TbetaR type II (TbetaR-II) and Smad2, Smad4, Smad6, and Smad7. Expression of each protein in the tumor was compared with that of the corresponding adjacent nonneoplastic thyroid parenchyma.
Results:
TbetaR-II expression was lost in 78% of the carcinomas. In the remaining 22%, TbetaR-II was preserved but Smad2 expression was lost. In all conventional adenomas, however, TbetaR-II expression was maintained. Furthermore, all tumors with normal expression of all proteins were adenomas.
Conclusions:
Downregulation of TbetaR-II is a consistent abnormality in follicular carcinomas and can be used to differentiate minimally invasive carcinomas from adenomas. Also, downregulation of Smad proteins is another mechanism by which carcinomas can become independent from TGF-beta-mediated growth inhibition.
Insights
Downregulation of transforming growth factor-beta receptor type II (TbetaR-II) is a key abnormality in follicular thyroid carcinomas, distinguishing them from adenomas. This loss of TbetaR-II and Smad proteins allows tumors to resist growth inhibition.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Transforming growth factor-beta (TGF-beta) signaling is crucial for regulating cell growth and is often dysregulated in epithelial cancers.
- Key components of the TGF-beta pathway include TGF-beta receptors (TbetaRs) and Smad proteins, which mediate downstream signaling.
- Resistance to TGF-beta-mediated growth inhibition is a hallmark of neoplastic progression in epithelial tissues.
Purpose of the Study:
- To investigate the expression patterns of TGF-beta signaling pathway components in follicular thyroid tumors.
- To determine if alterations in TbetaR-II and Smad protein expression can differentiate between benign follicular adenomas and malignant follicular carcinomas.
- To explore the role of TGF-beta pathway dysregulation in the pathogenesis of follicular thyroid neoplasia.
Main Methods:
- Immunohistochemistry was used to analyze the protein expression of TbetaR type II (TbetaR-II), Smad2, Smad4, Smad6, and Smad7 in 20 follicular thyroid neoplasms (11 adenomas, 9 carcinomas).
- Expression levels of these proteins in tumor tissues were compared to adjacent non-neoplastic thyroid parenchyma.
- Follicular thyroid neoplasms were classified as adenomas or minimally invasive follicular carcinomas based on established pathological criteria.
Main Results:
- Loss of TbetaR-II expression was observed in 78% of follicular carcinomas.
- In the remaining 22% of carcinomas, TbetaR-II was preserved, but Smad2 expression was lost.
- TbetaR-II expression was consistently maintained in all conventional adenomas, and adenomas showed normal expression of all investigated proteins.
Conclusions:
- Downregulation of TbetaR-II is a consistent finding in follicular thyroid carcinomas and serves as a potential diagnostic marker to distinguish them from adenomas.
- Alterations in Smad protein expression, alongside TbetaR-II loss, represent a mechanism by which follicular carcinomas achieve independence from TGF-beta-mediated growth inhibition.
- These findings highlight the critical role of TGF-beta pathway dysregulation in the malignant transformation of follicular thyroid tumors.